Results 61 to 70 of about 95,190 (307)

Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation

Advanced Science, EarlyView.
Native thioredoxin‐1 (TRX) stimulates proliferation and rescues stem cells and cancer cells from multiple stressors by suppressing p53 and inhibiting ferroptosis via GPX4/SLC7A11 upregulation mediated by enhanced KLF4 expression and p53 promoter binding.
Jian Wu, Xiaobei Wang, Parker Mathews, Shaima Jabbar, Min Zhang, Haim Moskowitz, Wei Duan, David P. Nichols, George William Schaaf, John D. Olson, Andrew N. Macintyre, J. Daniel Bourland, Ivan Spasojevic, Jen‐Tsan Ashley Chi, Joel Ross, Nelson Chao, J. Mark Cline, Peter B. Heifetz, Yubin Kang   +18 more
wiley   +1 more source

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior

Haematologica, 2010
Background The concept of “accelerated” chronic lymphocytic leukemia is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form of chronic lymphocytic leukemia nor its clinical correlates and ...
Eva Giné, Antoni Martinez, Neus Villamor, Armando López-Guillermo, Mireia Camos, Daniel Martinez, Jordi Esteve, Xavier Calvo, Ana Muntañola, Pau Abrisqueta, Maria Rozman, Ciril Rozman, Francesc Bosch, Elias Campo, Emili Montserrat   +14 more
doaj   +1 more source

Leukostasis in Chronic Lymphocytic Leukemia

American Journal of Case Reports, 2020
BACKGROUND Chronic lymphocytic leukemia (CLL) is a mature B cell lymphocytic neoplasm that has an indolent clinical course. Therefore, not all patients with CLL require treatment at the time of diagnosis. Hyperleukocytosis (white blood cell count, >100×10⁹/L) is present in a large proportion of patients with CLL. However, symptomatic hyperleukocytosis (
Navdeep Singh, Gurinder Sidhu, Lech Dabrowski, Sandeep Singh Lubana   +3 more
openaire   +3 more sources

Tead1a Initiates Transcriptional Priming Through the TEAD1a/YAP‐Notch1‐Spi1/Cebpα Axis to Promote Neutrophil Fate

Advanced Science, EarlyView.
This study discovered that the protein TEAD1a is crucial for neutrophil development. In zebrafish models, disrupting TEAD1a or its interaction with partner protein YAP1 caused severe neutrophil deficiency. TEAD1a functions during the early HSC stage, activates Notch1 signaling in the GMP stage, and triggers Spi1 and Cebpα to drive neutrophil terminal ...
Wang Yiqin, Yang Ruimeng, Wang Peihong, Liu Xiaohui, Yuan Hao, Huang Hongli, Zhou Yongjian, Xie Baoshu   +7 more
wiley   +1 more source

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

Hepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou, Kaiwei Jia, Suyuan Wang, Zhenyang Li, Yunhui Li, Shan Lu, Yingyun Yang, Liyuan Zhang, Mu Wang, Yue Dong, Luxin Zhang, Wannian Zhang, Nan Li, Yizhi Yu, Xuetao Cao, Jin Hou   +15 more
wiley   +1 more source

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases

BMC Cancer, 2019
Background Chronic lymphocytic leukemia is a malignancy with good prognosis. However, the incidence of secondary tumors increases every year after the diagnosis of chronic lymphotcytic leukemia. One of the induced secondary tumors is prostate cancer. For
Yinjie Zhu, Yanqing Wang, Zhiyu Qian, Jiahua Pan, Qiang Liu, Baijun Dong, Wei Xue   +6 more
doaj   +1 more source

Variations in Innate Immune Cell Subtypes Correlate with Epigenetic Clocks, Inflammaging and Health Outcomes

Advanced Science, EarlyView.
This study uses a high‐resolution DNA methylation reference panel for 19 immune cell‐types, as well as transcriptomic, metabolomic, and large population cohort data to show that age‐related epigenetic heterogeneity within monocytes correlates with inflammaging, biological age, and all‐causemortality, and does so more strongly than existing monocyte ...
Xiaolong Guo, Josephine A. Robertson, Andrea Aparicio, Kirsten Seale, Qingwen Chen, Anne Richmond, Zhaozhen Du, Mahnoor Sulaiman, Shijie C Zheng, Esteban Ballestar, Charlotte AM Cecil, Bastiaan T Heijmans, Steve Horvath, Varun B. Dwaraka, Jessica Lasky‐Su, Ryan Smith, Riccardo E. Marioni, Andrew E Teschendorff   +17 more
wiley   +1 more source

Src Reduces Neutrophil Extracellular Traps Generation and Resolves Acute Organ Damage

Advanced Science, EarlyView.
Src reduces neutrophil extracellular traps (NETs) generation and resolves acute organ damage. Src directly activates RAF1 by regulating phosphorylation at the Ser 621 site and mediates the RAF/MEK/ERK pathway, thereby affecting the intracellular ROS production. Alternatively, Src activates the RAF1/MEK/ERK pathway by mediating PKC phosphorylation.
Guotao Lu, Fei Han, Yaodong Wang, Chenchen Yuan, Qingtian Zhu, Tianqi Xia, Lin Chen, Xiaowu Dong, Yanbing Ding, Weiming Xiao, Yuyan Zhang, Jiajia Pan, Hongwei Xu, Weiwei Chen, Bo Tu, Wei Li, Fei Wang, Weijuan Gong, Lianghao Hu   +18 more
wiley   +1 more source

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations

Haematologica, 2018
Despite the recent discovery of recurrent driver mutations in chronic lymphocytic leukemia, the genetic factors involved in disease onset remain largely unknown.
Andreas Agathangelidis, Viktor Ljungström, Lydia Scarfò, Claudia Fazi, Maria Gounari, Tatjana Pandzic, Lesley-Ann Sutton, Kostas Stamatopoulos, Giovanni Tonon, Richard Rosenquist, Paolo Ghia   +10 more
doaj   +1 more source

Alemtuzumab in Chronic Lymphocytic Leukemia

Current Oncology, 2007
Questions: (1) With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (CLL)? (2) What toxicities are associated with the use of alemtuzumab? (3) Which patients are more likely—or less likely—
Fraser, G., Smith, C.A., Imrie, K., Meyer, R.   +3 more
openaire   +3 more sources